DETECTION OF OXA COMPLEX CONTAINING MANGANESE BY LDI MASS SPECTROMETRY

17th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings, Volume I) (2024) [G-06-P, pp. 269-272]

AUTHOR(S) / АУТОР(И): Filip Veljković , Bojan Božić , Milovan Stoiljković , Ivana Stajčić , Bojan Janković , Marija Janković  and Suzana Veličković

Download Full Pdf   

DOI: 10.46793/Phys.Chem24I.269V

ABSTRACT / САЖЕТАК:

Complexes containing transition metal ions, especially with oxaprozin, have significant potential for cancer treatment. In this study, laser desorption/ionization (LDI) with a commercial matrix- assisted LDI time-of-flight mass spectrometer was used to investigate the possibility of detecting an oxaprozin complex with Mn, [(C18H14NO3)2Mn]. The results showed that the LDI mass spectrum of [(C18H14NO3)2Mn] (obtained at a laser intensity of 2900 to 3400 a.u., an accelerating voltage of 18000 V, a grid voltage of 80 % and extraction delay times of 100 to 300 ns) contains three groups of peaks corresponding to the molecular ion at m/z 639.79, 640.77, 641.49, the sodium adduct at m/z 661.76, 662.76, 663.77 and the potassium adduct at m/z  677.71, 678.69. Under these conditions, the experimental isotopology exactly matched the theoretical values of the oxaprozine complex with Mn. LDI-MS thus proves to be promising for the characterization of new organometallic compounds

KEYWORDS / КЉУЧНЕ РЕЧИ:

ACKNOWLEDGEMENT / ПРОЈЕКАТ:

This work was financially supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, contract numbers: 451-03-66/2024-03/200017 and 451-03- 66/2024-03/200178.

REFERENCES / ЛИТЕРАТУРА:

  • M. A. al-Faks, M. C. Pugh, Orthop. Rev., 21 (1992) 558–563.
  • J. J. Talley, D. L. Brown, J. S. Carter, M. J. Graneto, C. M. Koboldt., J. L. Masferrer, W. E. Perkins, R. S. Rogers, A. F. Shaffer, Y. Y. Zhang, B. S. Zweifel, K. Seibert, J. Med. Chem., 43 (2000) 775–777.
  • B. D. Bozic, J. R. Rogan, D. D. Poleti, N. P. Trisovic, G. S. Uscumlic, Chem Pharm Bull.,60 (2012) 865–869.
  • J. A. Baron, Prog Exp Tumor Res., 37 (2003) 1–24.
  • R. Ettarh, A. Cullen, A. Calamai, Pharmaceuticals (Ott.), 3 (2010) 2007–2021.
  • Y. Iizuka, E. Sakurai, Y. Tanaka, Riken Review, 35 (2001) 3–4.
  • S. J. Lippard, J. M. Berg, “Principles of Bioinorganic Chemistry”, University Science Books, Mill Valley, 1994.
  • R. K. Szilagyi, P. A. Bryngelson, M. J. Maroney, B. Hedman, K. O. Hodgson, E. I. Solomon, J Am Chem Soc.,126 (2004) 3018–3019.
  • M. H. Stipanuk, “Biochemical, Physiological & Molecular Aspects of Human Nutrition,” 2nd ed., W. B. Saunders Company, New York, 2006.
  • M. Kobayashi, S. Shimizu, Eur J Biochem., 261 (1999) 1–9.
  • P. Lay, T. Hambley, WO Patent 109843, 2007.
  • D. K. Saha, S. Padhye, S. Padhye, Met Based Drugs, 8 (2001) 73–77.
  • J. H. Banoub, R. P. Newton, E. Esmans, D. F. Ewing, G. Mackenzie, Chem. Rev., 105 (2005) 1869.
  • M. Wyatt, J. Mass Spec., 46 (2011) 712.
  • W. Henderson, J. S. McIndoe, Mass Spectrometry of Inorganic, Coordination and Organometallic Compounds, 2005.